LT4989B - Apolipoproteino b-100 epitopo mimeziniai peptidai, jų konkatemerai ir modifikuotieji peptidai, ir juos turinti vakcinos kompozicija - Google Patents

Apolipoproteino b-100 epitopo mimeziniai peptidai, jų konkatemerai ir modifikuotieji peptidai, ir juos turinti vakcinos kompozicija Download PDF

Info

Publication number: LT4989B
Authority: LT; Lithuania
Prior art keywords: peptide; mimetic; concatemer; peptides; apoliprotein
Prior art date: 2000-09-04

Application number

LT2002051A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2002051A (en

Inventor

Hyo Joon Kim

Original Assignee

Hyo Joon Kim

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-04

Filing date

2002-04-29

Publication date

2003-01-27

2001-09-04 Priority claimed from KR10-2001-0054005A external-priority patent/KR100472841B1/ko

2002-04-29 Application filed by Hyo Joon Kim filed Critical Hyo Joon Kim

2002-09-25 Publication of LT2002051A publication Critical patent/LT2002051A/xx

2003-01-27 Publication of LT4989B publication Critical patent/LT4989B/lt

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 126
108091028732 Concatemer Proteins 0.000 title claims abstract description 35
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 34
229960005486 vaccine Drugs 0.000 title claims abstract description 31
239000000203 mixture Substances 0.000 title claims abstract description 30
108091005601 modified peptides Proteins 0.000 title claims abstract description 20
208000008589 Obesity Diseases 0.000 claims abstract description 22
235000020824 obesity Nutrition 0.000 claims abstract description 22
239000000243 solution Substances 0.000 claims description 40
108020004414 DNA Proteins 0.000 claims description 23
239000013598 vector Substances 0.000 claims description 23
238000002347 injection Methods 0.000 claims description 13
239000007924 injection Substances 0.000 claims description 13
238000000034 method Methods 0.000 claims description 12
239000000126 substance Substances 0.000 claims description 8
239000013604 expression vector Substances 0.000 claims description 7
238000006467 substitution reaction Methods 0.000 claims description 5
238000012217 deletion Methods 0.000 claims description 4
230000037430 deletion Effects 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
239000000839 emulsion Substances 0.000 claims description 3
239000012634 fragment Substances 0.000 claims description 3
239000001828 Gelatine Substances 0.000 claims description 2
239000000443 aerosol Substances 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
239000008187 granular material Substances 0.000 claims description 2
239000006187 pill Substances 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
239000006188 syrup Substances 0.000 claims description 2
235000020357 syrup Nutrition 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
230000001131 transforming effect Effects 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 3
229920001184 polypeptide Polymers 0.000 claims 2
230000002068 genetic effect Effects 0.000 claims 1
102000006991 Apolipoprotein B-100 Human genes 0.000 abstract 1
108010008150 Apolipoprotein B-100 Proteins 0.000 abstract 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 34
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 33
241000699670 Mus sp. Species 0.000 description 24
239000013612 plasmid Substances 0.000 description 23
108090000623 proteins and genes Proteins 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 20
239000000499 gel Substances 0.000 description 19
210000004027 cell Anatomy 0.000 description 18
239000000872 buffer Substances 0.000 description 17
239000004202 carbamide Substances 0.000 description 17
XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 13
235000012000 cholesterol Nutrition 0.000 description 13
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
108010007622 LDL Lipoproteins Proteins 0.000 description 11
102000007330 LDL Lipoproteins Human genes 0.000 description 11
108010028554 LDL Cholesterol Proteins 0.000 description 10
239000012528 membrane Substances 0.000 description 10
101100189471 Mus musculus Pbx1 gene Proteins 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
229940092253 ovalbumin Drugs 0.000 description 9
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 8
238000008214 LDL Cholesterol Methods 0.000 description 8
108010058846 Ovalbumin Proteins 0.000 description 8
239000011347 resin Substances 0.000 description 8
229920005989 resin Polymers 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
150000003626 triacylglycerols Chemical class 0.000 description 8
230000037396 body weight Effects 0.000 description 7
239000002609 medium Substances 0.000 description 7
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
238000001262 western blot Methods 0.000 description 7
241001596967 Escherichia coli M15 Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
238000000746 purification Methods 0.000 description 6
108010023302 HDL Cholesterol Proteins 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
239000000427 antigen Substances 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000001962 electrophoresis Methods 0.000 description 5
229940083575 sodium dodecyl sulfate Drugs 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
201000001320 Atherosclerosis Diseases 0.000 description 4
102100029727 Enteropeptidase Human genes 0.000 description 4
108010013369 Enteropeptidase Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108010067902 Peptide Library Proteins 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108091006054 His-tagged proteins Proteins 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
239000002033 PVDF binder Substances 0.000 description 3
108010062497 VLDL Lipoproteins Proteins 0.000 description 3
239000012190 activator Substances 0.000 description 3
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
229960005542 ethidium bromide Drugs 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000013116 obese mouse model Methods 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
229920002981 polyvinylidene fluoride Polymers 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012360 testing method Methods 0.000 description 3
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102000000853 LDL receptors Human genes 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
102000004882 Lipase Human genes 0.000 description 2
239000004367 Lipase Substances 0.000 description 2
108090001060 Lipase Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000008272 agar Substances 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
-1 cachets Substances 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
235000019421 lipase Nutrition 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000006174 pH buffer Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940023041 peptide vaccine Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
PRBJTPCAKUBWAO-UHFFFAOYSA-N 2-aminoacetic acid;pentanedial Chemical compound NCC(O)=O.O=CCCCC=O PRBJTPCAKUBWAO-UHFFFAOYSA-N 0.000 description 1
WBTFUMUXXHWTLD-UHFFFAOYSA-N 4-phenoxybutan-2-ol Chemical compound CC(O)CCOC1=CC=CC=C1 WBTFUMUXXHWTLD-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
241000037164 Collema parvum Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
108010010234 HDL Lipoproteins Proteins 0.000 description 1
102000015779 HDL Lipoproteins Human genes 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000015580 Increased body weight Diseases 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010013563 Lipoprotein Lipase Proteins 0.000 description 1
102100022119 Lipoprotein lipase Human genes 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
241001529936 Murinae Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
101150103639 PB1 gene Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000007844 bleaching agent Substances 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000020974 cholesterol intake Nutrition 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
IUJLOAKJZQBENM-UHFFFAOYSA-N n-(1,3-benzothiazol-2-ylsulfanyl)-2-methylpropan-2-amine Chemical compound C1=CC=C2SC(SNC(C)(C)C)=NC2=C1 IUJLOAKJZQBENM-UHFFFAOYSA-N 0.000 description 1
FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000016446 peptide cross-linking Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
108700010839 phage proteins Proteins 0.000 description 1
108010014366 phagocytosis-inhibitory factor Proteins 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Obesity (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

LT2002051A 2000-09-04 2002-04-29 Apolipoproteino b-100 epitopo mimeziniai peptidai, jų konkatemerai ir modifikuotieji peptidai, ir juos turinti vakcinos kompozicija LT4989B (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20000052055		2000-09-04
KR10-2001-0054005A KR100472841B1 (ko)	2000-09-04	2001-09-04	아포지단백질 비-100의 에피토프에 대한 모조 펩타이드,그들의 연쇄물 또는 변형체와 이들을 함유하는 백신 조성물

Publications (2)

Publication Number	Publication Date
LT2002051A LT2002051A (en)	2002-09-25
LT4989B true LT4989B (lt)	2003-01-27

Family

ID=26638363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2002051A LT4989B (lt)	2000-09-04	2002-04-29	Apolipoproteino b-100 epitopo mimeziniai peptidai, jų konkatemerai ir modifikuotieji peptidai, ir juos turinti vakcinos kompozicija

Country Status (18)

Country	Link
US (1)	US6825318B2 (cs)
EP (1)	EP1315517B1 (cs)
JP (1)	JP2004508029A (cs)
CN (1)	CN1231262C (cs)
AU (1)	AU8628601A (cs)
BG (1)	BG106655A (cs)
BR (1)	BR0107175A (cs)
CA (1)	CA2389739A1 (cs)
CZ (1)	CZ20021571A3 (cs)
EE (1)	EE200200238A (cs)
HU (1)	HUP0203251A2 (cs)
IL (1)	IL149379A0 (cs)
LT (1)	LT4989B (cs)
MX (1)	MXPA02004505A (cs)
NO (1)	NO20022147L (cs)
RU (1)	RU2313536C2 (cs)
SK (1)	SK6312002A3 (cs)
WO (1)	WO2002020040A1 (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL379196A1 (pl) *	2003-06-11	2006-07-24	Schering Aktiengesellschaft	Nowe zmodyfikowane cząsteczki koryny posiadające substytut sekwencji aktywacji i ich zastosowanie
KR100639397B1 (ko) *	2004-03-18	2006-10-26	(주)에스제이바이오메드	항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
US20070054298A1 (en) *	2005-08-12	2007-03-08	Kent Kirshenbaum	Methods for enzyme-mediated coupling of oligomers
WO2007075335A2 (en) *	2005-12-16	2007-07-05	The Regents Of The University Of California	Modulation of in utero immune programming
US8961982B2 (en) *	2005-12-16	2015-02-24	The Regents Of The University Of California	Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
RU2418005C2 (ru) *	2006-09-25	2011-05-10	ЭсДжей БАЙОМЕД ИНК.	Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
CN103520713B (zh) *	2013-10-16	2015-10-28	西北农林科技大学	一种ApoB100酵母重组疫苗及其制备方法和应用
EP3463416A1 (en)	2016-05-31	2019-04-10	CardioVax, LLC	Methods for diagnosing and treating systemic lupus erythematosus
US10858422B2 (en)	2016-05-31	2020-12-08	Abcentra, Llc	Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3215310A1 (de) *	1982-04-23	1983-10-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur bestimmung der low density lipoproteine (ldl) und reagenz zu seiner durchfuehrung
US6309853B1 (en) *	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2283474A1 (en) *	1997-03-04	1998-09-11	Bio-Technology General Corp.	Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
AU2801299A (en) *	1998-03-04	1999-09-20	Bio-Technology General Corporation	Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
EP1267908B1 (en) *	2000-03-03	2004-05-06	GlaxoSmithKline Biologicals S.A.	Vaccine for the treatment of atherosclerosis

2001
- 2001-09-04 CN CNB018030572A patent/CN1231262C/zh not_active Expired - Fee Related
- 2001-09-04 JP JP2002524523A patent/JP2004508029A/ja active Pending
- 2001-09-04 EP EP01965715A patent/EP1315517B1/en not_active Expired - Lifetime
- 2001-09-04 EE EEP200200238A patent/EE200200238A/xx unknown
- 2001-09-04 HU HU0203251A patent/HUP0203251A2/hu unknown
- 2001-09-04 IL IL14937901A patent/IL149379A0/xx unknown
- 2001-09-04 AU AU86286/01A patent/AU8628601A/en not_active Abandoned
- 2001-09-04 RU RU2003109439/13A patent/RU2313536C2/ru not_active IP Right Cessation
- 2001-09-04 CA CA002389739A patent/CA2389739A1/en not_active Abandoned
- 2001-09-04 CZ CZ20021571A patent/CZ20021571A3/cs unknown
- 2001-09-04 SK SK631-2002A patent/SK6312002A3/sk unknown
- 2001-09-04 BR BR0107175-0A patent/BR0107175A/pt not_active Application Discontinuation
- 2001-09-04 WO PCT/KR2001/001492 patent/WO2002020040A1/en not_active Ceased
- 2001-09-04 MX MXPA02004505A patent/MXPA02004505A/es unknown
2002
- 2002-04-25 BG BG106655A patent/BG106655A/bg unknown
- 2002-04-29 LT LT2002051A patent/LT4989B/lt not_active IP Right Cessation
- 2002-05-03 NO NO20022147A patent/NO20022147L/no not_active Application Discontinuation
2003
- 2003-03-04 US US10/378,707 patent/US6825318B2/en not_active Expired - Lifetime

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALVING CR, WASSEF NM, POTTER M.: "Antibodies to cholesterol: biological implications of antibodies to lipids", CURR TOP MICROBIOL IMMUNOL., 1996, pages 181 - 186, XP002923267
BRECHER G, WAXLER SH.: "Obesity in albino mice due to single injections of goldthioglucose", PROC SOC EXP BIOL MED., 1949, pages 498 - 501
BROWN MS, GOLDSTEIN JL: "Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis", ANNU REV BIOCHEM., 1983, pages 223 - 261
CARL R. ALVING ET AL.: "Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1996, pages 40 - 49, XP001095396, DOI: doi:10.1016/S0022-2143(96)90164-X
CARL R. ALVING ET AL.: "Naturally occurring autoantibodies to cholesterol in humans", BIOCHEMICAL SOCIETY TRANSACTIONS, 1989, pages 637 - 639
DALUM I ET AL.: "Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope", MOL IMMUNOL., 1997, pages 1113 - 1120, XP002920190, DOI: doi:10.1016/S0161-5890(97)00147-8
JM BAILEY: "Cholesterol vaccines", SCIENCE, 1994, pages 1067 - 1068, XP002310090
W PALINSKI ET AL.: "Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis", PROC NATL ACAD SCI USA., 1995, pages 821 - 825, XP002951783, DOI: doi:10.1073/pnas.92.3.821

Also Published As

Publication number	Publication date
EP1315517B1 (en)	2010-10-20
CA2389739A1 (en)	2002-03-14
SK6312002A3 (en)	2002-09-10
JP2004508029A (ja)	2004-03-18
BR0107175A (pt)	2002-07-02
RU2003109439A (ru)	2004-07-20
BG106655A (bg)	2004-08-31
CN1392798A (zh)	2003-01-22
US6825318B2 (en)	2004-11-30
US20030211997A1 (en)	2003-11-13
MXPA02004505A (es)	2004-09-10
CZ20021571A3 (cs)	2002-09-11
IL149379A0 (en)	2002-11-10
WO2002020040A1 (en)	2002-03-14
EP1315517A1 (en)	2003-06-04
LT2002051A (en)	2002-09-25
NO20022147D0 (no)	2002-05-03
AU8628601A (en)	2002-03-22
HUP0203251A2 (hu)	2003-01-28
NO20022147L (no)	2002-05-03
CN1231262C (zh)	2005-12-14
RU2313536C2 (ru)	2007-12-27
EE200200238A (et)	2003-06-16
EP1315517A4 (en)	2005-02-09

Legal Events

Date	Code	Title	Description
2004-04-26	MM9A	Lapsed patents	Effective date: 20030904

Publication	Publication Date	Title
US6410022B1 (en)	2002-06-25	Modulation of cholesteryl ester transfer protein (CETP) activity
US6699973B1 (en)	2004-03-02	Antibodies to peptides that target GIT receptors and related methods
LT4989B (lt)	2003-01-27	Apolipoproteino b-100 epitopo mimeziniai peptidai, jų konkatemerai ir modifikuotieji peptidai, ir juos turinti vakcinos kompozicija
EP0672136B1 (en)	2000-03-08	Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
KR100956893B1 (ko)	2010-05-11	항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
TW200911282A (en)	2009-03-16	Pharmaceutical compound
AU2004262472A1 (en)	2005-02-17	Targeted therapeutic vaccine against P-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers
JP2010504094A5 (cs)	2012-07-12
KR100639397B1 (ko)	2006-10-26	항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
KR100472841B1 (ko)	2005-03-07	아포지단백질 비-100의 에피토프에 대한 모조 펩타이드,그들의 연쇄물 또는 변형체와 이들을 함유하는 백신 조성물
JP2003511061A (ja)	2003-03-25	変更された化学結合体化特性を有するａｂ５毒素ｂサブユニット変異体
AU2007200834B2 (en)	2010-10-14	Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
US5871739A (en)	1999-02-16	Pharmaceutical composition
HK1050857A (en)	2003-07-11	Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
JP2000505645A (ja)	2000-05-16	カルシウム結合プロテオリピド組成物および方法
HK1026119A (en)	2000-12-08	Mammalian nonhuman transgenic animal having a constitutive or inducible expression of the human endonexin ii gene or its muteins or its fragments